secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0001104659-22-083169
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q2 royalties up 7% to $111.7M; acquires Entasis, agrees to buy La Jolla
--------------------------------------------------------------------------------

- Royalties increased 7% to $111.7M in Q2 2022 vs Q2 2021.
- Income from operations decreased 14% to $82.6M due to Entasis consolidation.
- Completed acquisition of remaining ~40% of Entasis for $2.20/share ($42M total).
- Entered merger to acquire La Jolla Pharmaceutical for $6.23/share (~$149M enterprise value).
- Sold 15% stake in Theravance Respiratory Co. to Royalty Pharma for ~$282M upfront plus potential $50M milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465922083169/0001104659-22-083169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465922083169/tm2221883d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-083169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer